Last reviewed · How we verify
amibegron (SR58611A)
Amibegron is a beta-3 adrenergic receptor agonist.
Amibegron is a beta-3 adrenergic receptor agonist. Used for Symptomatic treatment of overactive bladder.
At a glance
| Generic name | amibegron (SR58611A) |
|---|---|
| Sponsor | Sanofi |
| Drug class | beta-3 adrenergic receptor agonist |
| Target | beta-3 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | Phase 3 |
Mechanism of action
It acts by stimulating the beta-3 adrenergic receptors in the bladder, leading to increased bladder capacity and reduced urge to urinate. This results in improved symptoms of overactive bladder.
Approved indications
- Symptomatic treatment of overactive bladder
Common side effects
- Dysuria
- Urinary retention
- Urinary tract infection
Key clinical trials
- Long Term Safety and Tolerability of SR58611 in Patients With Major Depressive Disorder (PHASE3)
- Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder (PHASE3)
- Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (SIRIUS) (PHASE3)
- Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine (PHASE3)
- Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine (PHASE3)
- Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (PHASE3)
- Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (PHASE3)
- Efficacy and Safety of SR58611A in Patients With a Generalized Anxiety Disorder (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |